Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy
RNA-seq (gene expression) · mouse · 14 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 14 samples: 3 × SHRFP vs 3 × SHSdc1 vs 3 × SHRFPIFN vs 3 × SHSdc1IFNGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapyScience advances · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE231357_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA964463 and SRA study SRP435320. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 14 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7265637 SHRFP-1 SHRFP
- GSM7265638 SHRFP-2 SHRFP
- GSM7265639 SHRFP-3 SHRFP
- GSM7265640 SHSdc1-1 SHSdc1
- GSM7265641 SHSdc1-2 SHSdc1
- GSM7265642 SHSdc1-3 SHSdc1
- GSM7265643 SHRFPIFNr-1 SHRFPIFN
- GSM7265644 SHRFPIFNr-2 SHRFPIFN
- GSM7265645 SHRFPIFNr-3 SHRFPIFN
- GSM7265646 SHSdc1IFNr-1 SHSdc1IFN
- GSM7265647 SHSdc1IFNr-2 SHSdc1IFN
- GSM7265648 SHSdc1IFNr-3 SHSdc1IFN
- GSM7265649 SH-RFP
- GSM7265650 SH-Sdc1
- GSE231355 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy [kdSdc1_RNAseq] 12 samples shares syndecan-1, anti-pd1, immunotherapy, facilitates, inhibition, anti-tumor, checkpoint, promotes
- GSE311831 Pertussis toxin-induced lymphocytosis enhances anti-tumor immune environments and improves the anti-PD1 treatment response in a squamous cell carcinoma model. 24 samples shares anti-pd1, anti-tumor
- GSE267158 Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy 48 samples shares immunotherapy, inhibition
- GSE234086 The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy 24 samples shares immunotherapy, checkpoint
- GSE264527 Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response 21 samples shares immunotherapy, inhibition
- GSE279924 Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma 20 samples shares immunotherapy, facilitates
- GSE300887 Sequential Platinum and PARP Inhibition Enhances PD1 Immunotherapy Efficacy in Murine Brca2 Mutated Pancreatic Cancer [RNAseq_1] 13 samples shares immunotherapy, inhibition
- GSE337208 scRNA seq. of PDAC models treated with Kras inhibitors in combination with checkpoint immunotherapy 9 samples shares immunotherapy, checkpoint
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.